drugset / Trial / NCT06739707
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
RandomizedSequentialDouble-blindTreatment
Summary
A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for healthy subjects with overweight or obesity
Timeline
- Start
- 2025-01-02
- Primary completion
- 2026-12
- Completion
- 2026-12
Outcome
Outcome not reported
Stopped (Business): “Due to sponsor decision - NO SAFETY ISSUES”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MD-18 | Unknown | 74 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 114 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 227 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 302 mg | Subcutaneous |
Indications
No indication recorded.